All Episodes

#137 $GEMI Crypto Pivot Chaos From Exchange Growth to Strategy Shock

#136 $COTY Beauty Boom to Bust The Earnings Shock Story

#135 $CIGL From Sky High Hype to Crash Landing The Concorde Collapse

#134 $ATRA From Breakthrough to Breakdown The Atara Biotech Story

#133 $IT Strong Guidance or Silent Slowdown Inside Gartner Miss

#132 $GO Growth Push or Costly Correction Inside Grocery Outlet Drop

#131 $ALIT Dividend Confidence or Collapse Inside Alight Unraveling

#130 $TCOM Antitrust Risk or Missed Warning Inside Trip.com Drop

#129 $SLNO Breakthrough Drug or Hidden Risk Inside Soleno Fallout

#128 $ODD Beauty Tech or Broken Ads Inside Oddity Tech Shock

#127 $NKTR Trial Trouble When Clinical Confidence Cracks

#126 $MNDY Growth Story or Slowing Momentum Inside monday.com Shift

#125 $EOSE Battery Boom or Broken Ramp Inside Eos Energy Miss

#124 $DRVN Restatement Shock When Financials Can’t Be Trusted

#123 $CWH Inventory Control or Margin Collapse Inside Camping World

#122 $CHOW Pump Hype or Engineered Collapse Inside ChowChow Cloud

#121 $BSX Heart Growth Hype or Hidden Slowdown Inside Boston Scientific

#120 $AQST FDA Delay Shock The Allergy Drug Setback Investors Missed

#119 $APO Wall Street Secrets The Apollo Epstein Controversy

#118 $SNOW Cloud Growth or Hidden Headwinds Inside the Snowflake Drop

#117 $NAVN IPO Turbulence What Investors Weren’t Told

#116 $LAKE Growth Strategy or Cracks in the Foundation Inside Lakeland Fallout

#115 $FBRT Dividend Cut Shock Income Investors Blindsided

#114 $CORT FDA Shock The Approval That Never Came

#113 $ZYXI Shocking Growth or Alleged Fraud Inside Zynex Collapse

#112 $ENPH Solar Shock Inventory Truth or Revenue Illusion

#111 $SMR Nuclear Promises or Costly Reality Unpacking the NuScale Lawsuit

#110 $OST Ostin Technology Scandal The Billion Dollar Pump and Dump Collapse

#109 $PYPL PayPal Branded Checkout Growth Story or Execution Breakdown

#108 $RGNX REGENXBIO Gene Therapy Breakthrough or Clinical Hold Shock

#107 $QURE uniQure Gene Therapy Breakthrough or Regulatory Reversal

#106 $KD Kyndryl Controls in Place or Confidence Collapse

#105 $INO Inovio Fast Track Dream or Regulatory Reality

#104 $PSFE Paysafe Payment Growth or Chargeback Shock

#103 $TCPC BlackRock TCP Capital Steady NAV or Valuation Shock

#102 $MREO Mereo BioPharma Stronger Bones or Shattered Expectations

#101 $RARE Ultragenyx Stronger Bones or Broken Thesis

#100 $ORCL Oracle AI Spending Surge or Revenue Reality Check

#099 $PLUG Plug Power Hydrogen Highway or Funding Freeze

#098 $PMI Picard Medical Artificial Heart or Artificial Hype

#097 $RR Richtech Robotics AI Collaboration or Market Manipulation

#096 $METC Ramaco Resources Rock Solid Opportunity or Potemkin Mine

#095 $BYND Beyond Meat Sizzles or Burns Investors

#094 $BRBR Shakes and Red Flags What BellRing Didn’t Tell Investors

#093 Smoked by Smart Digital: The $SDM Social Media Pump-and-Dump

#092 Mist Opportunity: The $VTGN Drug Trial That Vaporized Millions

#091 Concrete Delays and Cloudy Claims: The $CRWV Collapse

#090 Scent of a Sell-Off: The $BBWI Strategy That Backfired

#089 Flatlining Finances: The $ARDT IPO That Misdiagnosed Itself

#088 Security Breach, Security Pitch: The $FFIV Fallout

#087 Glitch in the Cloud: The $VRNS SaaS Collapse

#086 Coup-oops: The $CPNG Data Breach That Shook a Nation

#085 Student Debt Surprise: The $SLM Lawsuit You Didn't See Coming

#084 Buy Now Sue Later: The $KLAR IPO Blowup

#083 Meltdown Mode: The $FRMI Fallout After the Hype

#082 Cloudy with a Chance of Litigation: The $AGL Shakeup

#081 $ITGR Flatlines: Firefighters Fund Sues Over Shock Drop

#080 Feathers Fly at $OWL: Investors Cry Foul Over Redemption Freeze

#079 $STUB’s Post-IPO Faceplant StubHub Sued Over Cash Flow Collapse

#078 $SFM’s Organic Illusion Sprouts' Stock Tanks After “Tailwind” Talk Wilts

#077 $JYD’s 95 Percent Crash How Jayud’s Pump and Dump Unraveled

#076 $DEFT's Crypto Mirage DeFi Technologies’ “Low-Risk” Strategy Implodes

#075 $BTDR’s Crypto Chip Collapse Bitdeer’s SEALMINER Hype Turns into a Lawsuit

#074 $ARE's Megacampus Meltdown The Truth Behind Alexandria's $323M Bombshell

#073 $SKYE's Weight Loss Wipeout When Biotech Hype Meets Reality

#072 $PRGO's Formula for Disaster How Perrigo’s Baby Bet Backfired

#071 $TLX in Hot Water Telix Faces SEC Heat Over Drug Development Disclosures

#070 $PRMB’s Merger Meltdown From “Flawless” to a $2 Billion Blowup

#069 $LRN’s Ghost Students The EdTech Scandal That Rocked Wall Street

#068 $FLY and Fall Firefly’s IPO Burns Investors in Rocket Lawsuit

#067 $FCX Under Fire The Mudslide That Sparked a Shareholder Showdown

#066 Molina’s $MOH Meltdown Two Guidance Cuts One Lawsuit

#065 $AVTR Meltdown Avantor’s Lab-Grade Confidence Evaporates in Court

#064 $DXCM Drops the Ball DexCom’s Sensor Scandal Shocks Investors

#063 $INSP Implodes The Sleep Apnea Launch That Put Investors to Bed

#062 $KMX Misfires How CarMax’s “Tariff Turbo” Turned into a Legal Tailspin

#061 Chipwreck at $SNPS When Custom AI Deals Collide with Wall Street

#060 Chemical Reaction The $AVTR Lab Meltdown Lawsuit

#059 Contract Terminated The $KBR Military Move Meltdown

#058 Bottle Service and Balance Sheets The $RICK Tax Fraud Blowup

#057 Spreadsheet Sorcery The $MRX Accounting Smoke Show

#056 Firewall Smoke and Mirrors The $FTNT Refresh Cycle Fallout

#055 Cracks in the Foundation The $JHX Stock Slide Explained

#054 $BAX and the IV Pump That Sparked a Securities Storm

#053 $MLTX MoonLake’s Nanobody Nightmare

#052 $ATYR’s Biotech Hype Falls Flat in One Day

#051 $WPP’s Ad Forecast Flops into a Lawsuit

#050 $SVRA’s Inhaled Hype Hits a Wall

#049 Trouble in the Tint: What’s Going on with $TROX?

#048 $VFC’s Reinvent or Misrepresent The Vans Reset That Shocked Shareholders

#047 $CYTK’s Approval Delay The Biotech Oversight That Rocked Investors

#046 $FLR’s Bridge to Nowhere How Fluor’s Earnings Collapse Sparked a Class Action

#045 The $SVRA Smokescreen How a Missing Drug File Crushed Shareholders

#044 Pylarify Panic The $LNTH Lawsuit Wall Street Didn’t See Coming

#043 $TSLA Swerves Into Legal Trouble Are Robotaxis the New Risk?

#042 $NVO’s 25 Percent Problem

#041 $LMT Crashes Under Classified Pressure

#040 $SOC Slips on Spilled Hype

#039 $LINE Goes Cold Inside the IPO That Left Investors Out in the Cold

#038 $FLYW Grounded How Student Visas Crashed Flywire’s Growth Story

#037 $FI’s Clover Crisis The Truth Behind Fiserv’s Growth Claims

#036 $DOW Drops the Ball The Dividend Cut Heard Around Wall Street

#035 ALT-erred Expectations What Went Wrong at $ALT

#034 $XYZ Insider Trading Could Cost You Millions and 20 Years